Invitrogen: The Pioneer of Genetic Engineering | Golden Age

Invitrogen, founded in 1987 by Lyle Turner, has been at the forefront of genetic engineering and biotechnology. The company's early success was fueled by its development of the pUC18 plasmid, a crucial tool for cloning and gene expression. In 2006, Invitrogen acquired Dynal Biotech, expanding its portfolio of products and services. The company's influence extends beyond its products, with a Vibe score of 80, reflecting its significant cultural energy in the scientific community. Invitrogen's legacy continues to shape the biotech industry, with key people like David Eansor, former President of Invitrogen, contributing to its growth. As the biotech landscape continues to evolve, Invitrogen's impact will be felt for years to come, with potential applications in fields like gene editing and regenerative medicine.